Chinese Cancer Drugs Show Promise Against Chemotherapy in Global Trials
Two new cancer drugs developed in China, sacituzumab tirumotecan (sac-TMT) for endometrial cancer and izalontamab brengitecan (iza-bren) for lung cancer, have shown superior results to chemotherapy in late-stage trials. Sac-TMT reduced the risk of death by a third in endometrial cancer patients, while iza-bren nearly doubled progression-free survival in lung cancer patients with a specific mutation. These antibody-drug conjugates, being advanced globally by major pharmaceutical companies, represent a significant shift in cancer treatment and the pharmaceutical industry's landscape.
הידיעה ב-6 שורות · תקציר של baba
- Two new Chinese-developed cancer drugs, sac-TMT and iza-bren, show significant advantages over chemotherapy.
- Sac-TMT reduced death risk by 32% in advanced endometrial cancer patients.
- Iza-bren nearly doubled progression-free survival in advanced lung cancer patients with EGFR mutation.
- Both drugs are antibody-drug conjugates (ADCs) targeting specific proteins on cancer cells.
- Global pharmaceutical giants are acquiring rights to these innovative Chinese therapies.
- Results were presented at the ESMO congress and published in The Lancet.
Two new cancer therapies developed in China have demonstrated significant improvements over traditional chemotherapy in late-stage clinical trials, potentially heralding a major shift in the pharmaceutical industry. Sacituzumab tirumotecan (sac-TMT), developed by Kelun-Biotech and being advanced by MSD outside China, showed a one-third reduction in the risk of death for patients with advanced endometrial cancer. In a Phase 3 trial involving 776 women, sac-TMT extended median survival to 19 months compared to 12.1 months with chemotherapy, and also improved progression-free survival and tumor shrinkage rates.
Sac-TMT is an antibody-drug conjugate (ADC) that targets the TROP2 protein, delivering a chemotherapy payload directly to cancer cells. While side effects were noted in over half of patients, discontinuation rates due to adverse events were lower than with chemotherapy. The U.S. FDA has granted priority review for sac-TMT, with a decision expected by June 2027.
The second drug, izalontamab brengitecan (iza-bren), developed by Biokin and co-developed by SystImmune and Bristol Myers Squibb outside China, showed promise for advanced non-small cell lung cancer patients with a specific EGFR mutation. In a trial of 432 patients, iza-bren nearly doubled median progression-free survival to 11.1 months from 5.7 months compared to chemotherapy, and significantly increased tumor shrinkage rates.
Iza-bren is also an ADC, but it targets both EGFR and HER3 proteins. Although side effects were more frequent than with chemotherapy, the discontinuation rate was similar. This drug is particularly relevant for Asian patients where the EGFR mutation is more common. The success of these drugs highlights the growing influence of Chinese pharmaceutical companies, with major global players acquiring rights to their innovations, signaling a significant tectonic shift in the industry.
Both therapies were presented at the European Society for Medical Oncology (ESMO) congress in Madrid and published in The Lancet. The development and potential future availability of these drugs in countries like Israel will depend on factors such as regulatory approvals and inclusion in national drug formularies.
מוזכרים
אותו אירוע, כפי שכל מערכת דיווחה עליו בנפרד. פתחו כמה דיווחים כדי להשוות מה כל מערכת מדגישה, ומה היא משאירה בחוץ.
מרכז 1אחרים 1
